Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports

被引：1

作者：

Manapov, Farkhad ^{[1
,2
,3
]}

Nieto, Alexander ^{[1
]}

Kaesmann, Lukas ^{[1
,2
,3
]}

Taugner, Julian ^{[1
]}

Kenndoff, Saskia ^{[1
]}

Floersch, Benedikt ^{[1
]}

Guggenberger, Julian ^{[1
]}

Hofstetter, Kerstin ^{[1
]}

Kroeninger, Sophie ^{[1
]}

Lehmann, Janina ^{[1
]}

Kravutske, Helene ^{[1
]}

Pelikan, Carolyn ^{[4
]}

Belka, Claus ^{[1
,2
,3
]}

Eze, Chukwuka ^{[1
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiotherapy & Radiat Oncol, Marchioninistr 15, D-81377 Munich, Bavaria, Germany

[2] German Ctr Lung Res DZL, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany

[3] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany

[4] Helmholtz Zentrum Munchen, Immunoanalyt Tissue Control Immunocytes, Munich, Germany

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2023年 / 32卷 / 03期

关键词：

Checkpoint inhibition; durvalumab; interferon gamma; PD-L1; mutational landscape; non-small cell lung cancer; tumor-infiltrating lymphocytes; tumor microenvironment; CELL LUNG-CANCER; LOCAL-REGIONAL CONTROL; OPEN-LABEL; CONCURRENT CHEMORADIOTHERAPY; PREDICTIVE BIOMARKERS; ADJUVANT DURVALUMAB; PD-L1; EXPRESSION; NSCLC; CHEMORADIATION; IMMUNOTHERAPY;

D O I：

10.1080/13543784.2023.2179479

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

IntroductionThe growing body of real-life data on maintenance treatment with durvalumab suggests that immunological markers of the cancer host interplay may have significant effects on the efficacy of multimodal therapy in patients with unresectable stage III NSCLC.Areas coveredWe summarize real-world clinical data regarding this new tri-modal approach and report on potential biomarker landscape.Expert opinionThe obvious question posed in this context of a very heterogeneous inoperable stage III NSCLC disease is: How can we augment an ability to predict checkpoint inhibition success or failure? Which tools and biomarkers, which clinical metadata and genetic background are relevant and feasible? No single biomarker will ever fully dominate the unresectable stage III NSCLC space, so we advocate multilevel and multivariate analysis of biomarkers. In this particular opinion piece, we explore the impact of PD-L1 expression on tumor cells, neutrophil-to-lymphocyte ratio, EGFR and STK11 mutational status, interferon-gamma signature, and tumor-infiltrating lymphocytes among others.

引用

页码：187 / 200

页数：14

共 64 条

[1] Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation [J].

An, Josiah ;

Yan, Melissa ;

Yu, Nanmeng ;

Chennamadhavuni, Adithya ;

Furqan, Muhammad ;

Mott, Sarah L. ;

Loeffler, Bradley T. ;

Kruser, Timothy ;

Sita, Timothy L. ;

Feldman, Lawrence ;

Nguyen, Ryan ;

Pasquinelli, Mary ;

Hanna, Nasser H. ;

Abu Hejleh, Taher .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (08) :3608-3615

[2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[3] The Immunoscore: Colon Cancer and Beyond [J].

Angell, Helen K. ;

Bruni, Daniela ;

Barrett, J. Carl ;

Herbst, Ronald ;

Galon, Jerome .

CLINICAL CANCER RESEARCH, 2020, 26 (02) :332-339

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5] Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities [J].

Antonioli, Luca ;

Yegutkin, Gennady G. ;

Pacher, Pal ;

Blandizzi, Corrado ;

Hasko, Gyorgy .

TRENDS IN CANCER, 2016, 2 (02) :95-109

[6] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy [J].

Aredo, Jacqueline V. ;

Mambetsariev, Isa ;

Hellyer, Jessica A. ;

Amini, Arya ;

Neal, Joel W. ;

Padda, Sukhmani K. ;

McCoach, Caroline E. ;

Riess, Jonathan W. ;

Cabebe, Elwyn C. ;

Naidoo, Jarushka ;

Abuali, Tariq ;

Salgia, Ravi ;

Loo Jr, Billy W. ;

Diehn, Maximilian ;

Han, Summer S. ;

Wakelee, Heather A. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) :1030-1041

[7] Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program [J].

Avrillon, Virginie ;

Daniel, Catherine ;

Boisselier, Pierre ;

Le Pechoux, Cecile ;

Chouaid, Christos .

LUNG, 2022, 200 (01) :95-105

[8] "Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway [J].

Best, Sarah A. ;

Sutherland, Kate D. .

CELL CYCLE, 2018, 17 (14) :1696-1707

[9] KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition [J].

Binkley, Michael S. ;

Jeon, Young-Jun ;

Nesselbush, Monica ;

Moding, Everett J. ;

Nabet, Barzin Y. ;

Almanza, Diego ;

Kunder, Christian ;

Stehr, Henning ;

Yoo, Christopher H. ;

Rhee, Siyeon ;

Xiang, Michael ;

Chabon, Jacob J. ;

Hamilton, Emily ;

Kurtz, David M. ;

Gojenola, Linda ;

Owen, Susie Grant ;

Ko, Ryan B. ;

Shin, June Ho ;

Maxim, Peter G. ;

Lui, Natalie S. ;

Backhus, Leah M. ;

Berry, Mark F. ;

Shrager, Joseph B. ;

Ramchandran, Kavitha J. ;

Padda, Sukhmani K. ;

Das, Millie ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Alizadeh, Ash A. ;

Loo, Billy W. ;

Diehn, Maximilian .

CANCER DISCOVERY, 2020, 10 (12) :1826-1841

[10]

Bradley JD, 2019, J CLIN ONCOL, V37

← 1 2 3 4 5 6 7 →